Ronald Silver Sells 12,048 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) insider Ronald Silver sold 12,048 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $21,204.48. Following the completion of the sale, the insider now owns 279,655 shares of the company’s stock, valued at $492,192.80. This trade represents a 4.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Ironwood Pharmaceuticals Stock Up 3.2 %

IRWD stock traded up $0.06 during trading hours on Wednesday, hitting $1.94. The company’s stock had a trading volume of 3,432,794 shares, compared to its average volume of 3,904,621. The company has a market capitalization of $310.46 million, a PE ratio of -64.67 and a beta of 0.29. The stock has a 50 day moving average price of $3.63 and a two-hundred day moving average price of $4.18. Ironwood Pharmaceuticals, Inc. has a 12 month low of $1.59 and a 12 month high of $15.70.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on IRWD. Craig Hallum lowered their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 22nd. StockNews.com downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Finally, JMP Securities dropped their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.67.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. KBC Group NV raised its holdings in Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,198 shares in the last quarter. Journey Strategic Wealth LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $45,000. Catalyst Funds Management Pty Ltd bought a new position in Ironwood Pharmaceuticals during the fourth quarter worth about $47,000. Xponance Inc. acquired a new position in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $50,000. Finally, Wolverine Trading LLC bought a new stake in shares of Ironwood Pharmaceuticals in the third quarter worth about $51,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.